2 April 2020 - - US-based Charles River Laboratories International, Inc. (NYSE: CRL) has entered into a partnership with Irish-based software company Deciphex, a specialist in preclinical digital pathology software-as-a-service, the company said.

Pathology is typically regarded as a diagnostically complex, process-heavy discipline.

The advent of digital pathology was viewed as having high potential for delivering great productivity enhancement, however, that potential has yet to be fully realized.

By combining ergonomic digital pathology workflows with artificial intelligence, Deciphex's Patholytix Preclinical platform can help maximize pathologist productivity and deliver quality data to clients faster.

Deciphex's flagship product, Patholytix Preclinical, is an industry-recognized technology for developing a streamlined workflow that empowers pathologists to generate primary diagnostic or peer review results from their computer workstation faster than would be possible either with traditional microscopy processes or with stand-alone digital pathology software.

Through this agreement, in addition to Charles River being the exclusive contract research organization distributing the Patholytix Preclinical solution to clients, the organisations will work together to co-develop deep learning enabled tools to support accelerated pathology analytics.

By combining Deciphex's unique digital pathology solutions with Charles River's streamlined integrated drug discovery and development portfolio, Charles River clients will have access to an increasingly efficient, best-in-class platform.

Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts.

Deciphex are an Irish-based software company focussed on developing digital pathology software for clinical and toxicologic pathology. Our ambition is to deliver solutions that provide tangible improvements in productivity to pathologists, eliminating low-level tasks so they can focus on the critical content.